Variables | Numbers | B [95 % CI] | p value |
---|---|---|---|
Age | 340 | −1.91 [−3.238, −0.582] | 0.005 |
Sex | |||
Female | 200 | Reference | |
Male | 140 | −38.67 [−81.973, 4.633] | 0.080 |
BMI | |||
<18.5 | 170 | −21.54 [−64.197, 21.109] | 0.321 |
≥18.5 | 170 | Reference | |
HAART regimen | |||
Stavudine based | 219 | 25.57 [−34.277, 85.420] | 0.401 |
Zidovudine based | 72 | −17.53 [−87.25, 52.190] | 0.621 |
Tenofovir based | 49 | Reference | |
Baseline CD4 | |||
<100 | 5 | 188.75 [−9.859, 387.359] | 0.062 |
100–199 | 94 | 201.29 [2.916, 399.661] | 0.047 |
200–350 | 139 | 133.33 [−64.785, 81.773] | 0.186 |
>350 | 102 | Reference | |
WHO stage | |||
Stage 1 | 65 | Reference | |
Stage 2 | 95 | −15.96 [−78.139, 46.212] | 0.614 |
Stage 3 | 144 | 24.17 [−33.426, 81.773] | 0.179 |
Stage 4 | 36 | −63.89 [−157.331, 29.548] | 0.409 |
Educational status | |||
Not educated | 69 | Reference | |
Primary | 122 | 52.75 [−4.906, 110.408] | 0.073 |
Secondary | 106 | 40.11 [−18.174, 98.400] | 0.177 |
Tertiary | 42 | 40.113 [−76.277, 83.098] | 0.933 |